. >> next fda commissioner scott gottlieb and nih director francis collins testified about some of the latest medical innovation and research. topics before the senate h.e.l.p. committee included opioid epidemic research, stem cell innovation, and rare disease funding.

scott gottlieb is our guest.out that drug from yesterday $850,000 for a single treatment. but you either go blind or you get -- i'd try to -- >> the problem is trying to get the insurance companies to cover it. >> well, we're talking generics but that's a big number for the single treatment >>> plus the latest on the winter storm and the extremely cold weather gripping much of the country. it's cold because it's warm. plus patriots coach bill belichick with some words of wisdom for his players as the blizzard works its way toward new england. playoffs are coming up "squawk box" will be right back. . >>> coming up, the push for more access to generic drugs for the fda in 2018. we'll hear from fda commissioner scott gottlieb. >>> u.s. equity futures are in the green, dow opening almost 70 points higher. we're back in a moment >>> good morning, welcome back to "squawk box" here on cnbc, we're live at the nasdaq market set in times square. >>> among the stories front and center, jace pea repo.c. penneyg its year guid

scott gottlieb, the commissioner of food and drug. we'll have as i mentioned to senator murphy, we'll have a hearing next wednesday on another important part of the cures act which was the first reorganization of our mental health laws in a decade which senator cassidy and senator murphy played a major role in. senator murray and i will have each an opening statement then we'll introduce our panel of witnesses. our witnesses will have five minutes of questions. in 2007 doug oliver who is in the front row, i believe, a computer programmer began to have trouble seeing and after a near accident had his driver's license taken away and was declared legally behind. the culprit was a rare form of macular degeneration. doug moved to nashville where his doctor told him while there were no cures, doug could search online for a clinical trial. doug found a rejen tiff medicine clinical trial in florida where doctors took cells out of the bone marrow in his hip, spun them in a centrifuge and injected these into his eye. three days later he began t

scott gottlieb. is commissioner of food and drugs, ensuring our drugs and medical devices are safe and effective. he was formerly deputy commissioner of the same agency. he was confirmed on may ninth of this year. welcome again to our witnesses. dr. collins, let's begin with you. >> good morning and thank you, chairman alexander, ranking member murray and other distinguished committee members. it is an honor to be today with my college dr. scott gottlieb the commission of the fda. as you one of the 20% futures act aimed to catalyze a very important goal shared by all americans, to speed the pace at which scientific discoveries are translated into life-saving treatments and cures. we at nih actually really appreciate your leadership in passing this bipartisan act by a vote of 95 -4 innocent exactly one year ago today, december 7. this enhances authorities and resources in ways that will help us to achieve this goal. many thoughtful provisions are clear in the act such as reducing administrative burden

scott gottlieb inherited the problem, appointed by president trump as the new head of the fda. >> i think that this is one of the biggest public health crises facing this country. >> reporter: ever? >> ever. >> reporter: could the fda have stopped this? >> i don't know that we could have stopped it. i think a lot of people didn't do what they needed to do in the past or we wouldn't be in the situation we're in right now. >> reporter: watchdogs point to a timeline of missed opportunities to rein in the crisis starting with the approval of oxycontin in 1995. by 2013, with opioids ravaging the country, the fda approved another powerful opioid called zohydro, over the objections of a panel of experts who voted 11-2 against it. the epidemic has hit west virginia particularly hard. >> one little community of 340 people had 9 million pills coming into it. >> reporter: senator joe manchin spent a year lobbying the fda to put limits on prescription opioids like vicodin. >> i go up and testify before the advisory committee. boom, should have been a slam dunk, right? >> reporter: but it wasn't. betw

. >>> fda commissioner scott gottlieb and nih director francis collins testified last month about medical innovation. in their appearance before the senate health committee members also asked them about the opioid epidemic, rare disease funding and research into treating addicts nonmedically. also advances in stem cell research, alzheimer's and neurology. >> this is a bipartisan hearing. we have agreed on the subject and the witnesses. i would say every member of this committee would gree agree on t witnesses. this is entitled implementation of the cure act, progress and the path forward for medical innovation to hear from dr. francis collins, the

. >>> food and drug administration scott gottlieb announced a new process to approve new drugs. this is 35 minutes. >> thanks a lot. thanks for the opportunity to be here today. we had a dialogue over many years, and i appreciate the relationship we had talking about policy issues. i wrote a subsequent article saying what's taking you so long, josh. so i've been waiting for him to return the favor, and i just got a copy of it. so i appreciate it very much. thanks for the opportunity to be here today. thanks john hopkins for hoestin this, and pew for providing space. transparency can be a powerful tool for innovation. new platforms for visualizing large complex data sets present important new opportunities for the research and development community for regulators and for clinicians. it allows people to harness data to advance the safe and effective and efficient development for medical needs and to communicate information supporting regulatory decision making in ways that engender greater public confidence in those decisions. the fda's goal is to advance transparency without redu

commissioner scott gottlieb said tuesday. commissioner gout leave announced the actions just before a speech on fda transparency as a washington forum. the meeting attended by researchers and academics focused on 18 recommendations for making the agency's decision making less opaque. the suggestions were part of a report called blueprint for transparency. you can read more at washingtonpost.com and we covered commissioner gottlieb's remarks at the washington forum along with other panels about fda transparency.p. that's available online at c-span.org. we'll have live coverage of two rallies in washington, d.c. this week. today, the march for life. and on saturday, the women's march on washington. anti-abortion activists will gather at the national mall for the 45th annual march for life rally marking the industry of the supreme court's roe versus wade decision legalizing abortion in the united states. watch live coverage of the march for life rally today at noon eastern on c-span3. and on saturday, live coverage of the women'

>> it has great people like scott gottlieb, john kelly and the list goes on and on. really solid people around him and with those people he's accomplished a fair amount but he's his own worst enemy. >>paul: i want to get to that but i want to push back a little. the first six months were fairly chaotic in the white house, right? until he put john kelly and there you had some of the most vicious backsliding than i can remember covering politics, including what i call the steve bannon presidency. >> i would separate politics from policy. in the meantime, he got a new supreme court judge as kim mentioned. he got people in place to do the kinds of things he ran on. >>paul: then there is the worst enemy part of it. 39 percent, 40 percent approval rating despite what mary ascribes as policy success and a growing economy. how do you explain the 39 percent? >> he's a - - president. i think the policy is better than we have any right to expect. i think it's been a fantastic year. on his record. but, there is the side of him where he can be rude, undignified and boastful in tw

scott gottlieb as you know is a star. >> i think his vision for tobacco and trying to improve and reduceobacco around the world is very inspiring. >> harris: we are watching the president very closely here, imagine this. these are some of the most powerful business leaders in the world, 15 of them by my count at that table. in fact, the president of siemens said they are going to be investing in north carolina, and the president having a one-on-one with pretty much everybody in the room. we will keep that picture up because the president's back and forth with these leaders. i want to bring in my panel really quickly, bernard whitman is a former bill clinton pollster, amy holmes is here come up, political analyst for rasmussen reports. amy, this is a day in which the economy is already in focus, there are a lot of things going on that are positive for this administration. >> harris, i've actually had the opportunity to interview the swiss president of the american swiss chamber of commerce about president trump and his leadership economically and i can tell you, the word from switzerland

we talked about they come off ,atents and, scott gottlieb speeding up the approvals process and introducinghave confidence our new portfolio is going to be able to offset the other products. sayn fact, exactly what you , the fda has worked with companies to move them very fast. roche has the most out of companies. in the best interest of patients, it is allowing us to to these new medicines patients faster and quicker. >> will be set here last year we spent time talking about drug pricing because candidate trump talked about drug pricing. president trump has a knot. the pressure is still here. where are you feeling it most? struck pricing is an important topic and it is important in the context of the entire health care span. we are part of the solution to overall health care costs. hemophilia,cine for which is groundbreaking, has shown a reduction in hemophilia patients in terms of believes they have. a more convenient dosing regimen. once a week, once every two weeks, and ejection they can give themselves versus iv infusions. certainly it is a benefit for .he health care ofi am not accusi

people like scott pruitt at the epa, scott gottlieb at the fda and sort of an awareness that the hostilityo business -- almost as much as the actual regulations, but the overriding message from the obama administration thatç basically business was a problem -- that reversal, i think, has made a big difference in the economy this year. paul: all right. james, i'm going to come to you for the low points, or at least some of them. because i think there's this paradox here. you've got these sort of to successes, accomplishments of congress, but then why is he under 40% in the polls? how do you explain that? >> yeah. i think his -- if you could say the big failure of the year in contrast to the substantive accomplishments is his failure to sell himself politically to the american people. paul: still swing voters. >> he's still bumping along, and i think a lot of it is despite what is turning out to be a pretty significant record of achievement in year one, he often says things that even his supporters wish he didn't say, tweets things they wish he didn't tweet, and i thinkç it'a historically

the committee being briefed on energy production outlooks and fda commissioner scott gottlieb speakingt johns hopkins university. the afternoon, the housemates to consider a bill to create a special commemorative coin. the white house hold a symposium aimed at empowering women. the senate considers the reauthorization of part of the foreign intelligence surveillance act. c-span3, the global perception of the united states. next, we hear the supreme court oral argument in collins v. virginia, a case about warrantless searches. to search aermitted vehicle without a warrant if they have probable cause to believe that it had been involved in illegal activities. in this case, they will decide if that extends to a covered motorcycle on private poverty. this is about one hour. case will hear argument in 161027, collins

scott gottlieb.reat to see you >> thanks for being here >> we have so many things to talk about we'll talk about smoking and those issues let's talk about the flu that has been something that's been an issue around the globe and in the united states it's been virulent >> it was an early season. we think it will peak earlier. probably close to peaking. maybe a couple more weaks. weeks. the flu this season is less virulent, for the most part people are getting less sick, but that means there's more people walking around with the flew so more cases are getting transmitted because of that. that doesn't mean some people are getting very sick. the predominant strain, when they manufactured the vaccines it was a good match, but when they manufactured the vaccines, they manufacture them in eggs. you have to make the virus that will grow well in the eggs the eggs produce the antigen that goes into the vaccine when the virus was egg adapte, d it made it less protective so it's not as good vaccine. >> so it's a

fda commissioner scott gottlieb speaking at johns hopkins university. the afternoon, the housemates to consider a bill to create a special commemorative coin. the white house hold a symposium aimed at empowering women. the senate considers the reauthorization of part of the foreign intelligence surveillance act. c-span3, the global perception of the united states. next, we hear the supreme court oral argument in collins v. virginia, a case about warrantless searches. to search aermitted vehicle without a warrant if they have probable cause to believe that it had been involved in illegal activities. in this case, they will decide if that extends to a covered motorcycle on private poverty. this is about one hour. case will hear argument in 161027, collins versus virginia. >> may it please the court. the warrant requirement for the home cannot be overthrown by the automobile exception. under the commonwealth's argument, on probable cause alone, an officer may search a vehicle anywhere that he finds it and may go anywhere that he needs to in order to access

doctor scott gottlieb is on track to fast-track it. i read at least some of your book to say that some of this may never be found. some scientists it should not be found. i hope you will tell us what you think. should we not continue to find nonaddictive pain medicine ten suffering? the secondary i want to learn is what we can do from washington, d.c. we've tried to address the ravages of this. congress passed the comprehensive addiction recovery act of the 21st century cares hacked to give states and communities the tools and resources they need to combat the crisis. there's a provision by senators warning capital that made it clear pharmacies could only fill part of certain prescriptions that way a mob filling the pain prescription could ask only for three days worth of pills instead of 30 days he was prescribed. in addition it included for the $1 billion in state grants. were considering additional funding for treatment and to discover alternative pain medicines. we've held hearings on lifestyle changes such as exercising and eating

scott g gottlieb, commissioner of the food and drug administration. this is the first of two hearings we plan to have on this topic. the second will be noticed for tuesday, january 23rd. senator murray and i each have an opening statement, then i'm going to turn to senator alexander and senator casey for any opening remarks they might have. after that, we will introduce our panel of witnesses and hear their testimonies, and then each member will have up to five minutes for any remarks and questions. finishes first i would like to welcome the chairman and thank him for giving me the opportunity to hold the gavel today. this hearing discusses a topic that's critical to our national security and has seen many years of bipartisan work in this committee and in this congress. together, we have developed and strengthened the framework to ensure we are prepared for chemical, biologic, radiolodgic and other tlinhreats. the pandemic and all hazard preparedness act created a framework which has grown and changed as we've learned from each public health experienc

and doctor scott gottlieb commissioner for the fda. this is the first of two hearings we plan to have on this topic. the second will be noticed for tuesday, january 23rd. senator murray and i each have an opening statement. then i will turn to senator alexander and casey for opening remarks they might have.after that will introduce the panel of witnesses and we will hear their testimonies and then each member will have up to five minutes for any remarks and questions. first i would like to welcome the chairman and thank him for giving me the opportunity to hold the devil today. this hearing discusses a topic that is critical to the national security and has seen many years of bipartisan work in this committee and in this congress. together we have developed and strengthened the grammar to ensure that we are prepared for chemical, biological, radiological and other nuclear threats with the potential to jeopardize the health of all americans. the pandemic and preparedness act of 2006 crater framework which is grown and changed as we have

. >>> food and drug administration scott gottlieb

. >>> food and drug administration scott gottlieb announced a new process to approve new drugs. this is 35 minutes. >> thanks a lot. thanks for the opportunity to be here today. we had a dialogue over many years, and i appreciate the relationship we had talking abouol

being briefed on energy production outlooks and scott gottlieb speaking at johns hopkins university. in the afternoon, the house meets to consider a bill to create a special commemorative coin. the white house holds and imposing them -- a symposium. in the senate considers a reauthorization of the surveillance act. later on c-span3, foreign ambassadors discussed the form perception of the u.s. >> coming up in an hour, the week ahead in washington including the upcoming government funding deadline will be discussed i roll call white house

and to ensure health and safety for all americans and i was glad to see the fda commissioner scott gottlieb showed his commitment that the fda will accelerate the release of information about problematic products before they may officially be classified as recall items. we look forward to hearing from the fda today about what plans and benchmarks it's developed to implement the law and recommendations from the oig. we look forward to the fda immremii implementing the expert recommendations to provide staff to the office that overseas the fda labs which do play a critical role in food recalls. i thank the hhs oig for testifying today and commend its recent report in december as well as the early alert issued in june of 2016. where it builds on the pass work done by the oig and most notably, two reports related to two recalls in 2009 and 2011. >> the food safety modernization act and many in the december report are similar, if not the same as they were in 2009 and 2011. further, the gao raised concerns about fda's food recall process in 2012 and while fda says that its addressed many of the f

scott gottlieb starting off the conference. introductions under way. >> efforts to pass and implement the food safety modernization act, focus on medical devices, especially the potential of using the unique device identifier to improve monitoring devices throughout the product lifecycle. we have successfully worked on products 10 to courage innovation particularly around antibiotics and 10 to sure appropriate use of them. we focused on drug safety and transparency in the supply chain and especially on the safety of compounded drugs. among other things, pew submitted transparency to the task force back in 2010 if the. they touch on some of the topics we'll be discussing today. reading the background papers for today's meet regular mind med of a meeting we convened in a room directly above of us here a few years ago about regular plo predictability and what do we mean what we talk about that? one of the things that emerged from that is something you may touch on today, sometimes the fda asks for new data on applications late in

scott gottlieb as you know, a star. >> he is a star. his vision for tobacco and trying to improve and reduce the use of tobacco around the world is very inspiring. >> very good thank you very much. >> mr. president, thank you very much for having me tonight i serve the people of abb. we are a business in more than 100 countries of the world, but we have made the last eight years the u.s. an investment focus. we have deployed $13 billion of capital and bought some iconic brands in the u.s. a motor company, and we trust now in the process of closing the transaction to acquire ge industrial solutions a fantastic business in terms of install base it needs a little investment in terms of technology. >> did you get the right price a good price you always get a good price. i know who i deal with he always gets a good price. that's good. >> altogether, we have today now including the ge transaction, we have 26,000 people in the u.s. in more than 60 sites. nicely spread out all over the u.s. we have the classic copper and iron activities, the mo

scott gottlieb is on board to fast-track the effort within the bounds of safety and efficacy. but i read at least some of your book to say that this holy grail may never be found. even some scientist who say it should not be found. so hope you will tell us what you think about this. should we not continue to try to find nonaddictive pain medicine to relieve suffering without addiction? is that not the obvious antidote to opioid epidemic? the secretary of a dope to learn from you about is what we can do from washington, d.c. we have tried in a foreign waster dreads the ravages of this crisis which we've all experienced in our states, in 2016 congress passed a comprehensive addiction and recovery act, and the 21st century cures act to give states and communities those on the front lines the tools and resources they need to combat this crisis. for example, provision by senators warren and capital was included that made it clear pharmacies could only fill part of certain prescriptions like oxycodone, and opioid, that when a mom is going her sons pain medication could ask only for

question to these folks, could we set a target of addiction free by 2030, and francis collins and scott gottlieb said that is doable if you define it the right way and it is doable within the current scientific knowledge and technologically likely new term future, but if you were to give us a target, what would you tell us? mr. quinones: if i were to give you a target, we would all be in trouble. i would say that a target is good, and it is my hunch as an american that that is something to strive towards. it is always good to have a deadline, always good to have a goal, what that year should be and if humans can ever be a is debatable. i'm not sure that is possible. as i said in my testimony, to me, this is a supply story. i lived in mexico for 10 years. not having thought about it very deeply, i just adopted the idea that all our drug problem was demand-driven. senator kaine: there is a lot of evidence for that. you addressed a street corner dealer, another one pops up. demand is going to keep producing streetcorner dealers. mr. quinones: i agree, but the primer and all of that i believe is sup

our new fda commissioner scott gottlieb has been working on that issue by trying to get more genericsto market faster. i think anything that actually supports market-based approach to that is a good approach i think price controls and things of that nature which have been discredited and discarded in the past, i think those are not the kinds of things we want to go back to. >> in many ways, 2017 was a year where we've really seen a change to the way medicine gets delivered in terms of three approvals, one-time treatments immune no therapies for cancer, first gene therapy for a rare form of blindness. as you look at these models that we're seeing for one-time drug pricing, do you think they're the right models and the way we're paying for medicines, it's changing how would you evaluate that? >> i think you have to look at it by each therapeutic category. i think what's happening, we're moving to precision medicine the right drug for the right patient at the right time. sometimes that's a one-time administration sometimes it's another a longer administration. remember that the real cost

it puts american pharmaceutical companies on an even playing field and administration through scott gottliebt products to people who need them quicker. maria: you were in the middle of this controversy over the epipen. it wasn't so much epipen and the dollar amount but the system. taken down overnight, amazon changed business? >> i think amazon figured out how to change it. it is difficult, we need to disruption in the system. >> talk about the venture business, i have no idea, a $10 billion market a $100 billion market but i can tell you student loans, parenting, these are trillion dollar markets today ripe for disruption. maria: will the president get the democrats to agree to $18 billion for the wall? >> the president campaign strongly on a border wall, he was elected president. it is incumbent on congress to get that done. >> can't blame anybody for coming to the greatest country on earth but there is a right way and wrong way, you have to do the right way, you can't be part of the greatest country on earth and not respected law, can't have it both ways, this president has made it clear.

important juncture in science, great new products coming to market, the administration through scott gottlieb to get products to people who need them quicker. >> so he is moving products faster. >> absolutely including proportionally generic products that is what creates the price competition that drives down health care costs. >> great point, ken that is what i want to ask you about, in terms of growth, in terms of pricing two of the biggest issues, in your industry right now what are you expecting this year. >> i think first of all, people have to look at facts, last year, pricing for a branded excuse me branded products increased 3.5% slowest growth in many, many years the challenge is while the rebates that are intensively negotiated between pharmaceutical companies and people in supply chain insurance are increasing, by the way, nearly doubled between 2013 and 2015. the problem is the cost to the patient at the counter is increasing. at a much faster rate. >> why? >> so we have well we have situation right now, where the rebates that are being negotiated are not being passed through whic

being briefed on energy production outlooks and scott gottlieb speaking at johns hopkins university. in the afternoon, the house meets to consider a bill to create a special commemorative coin. the white house holds and imposing them -- a symposium. in the senate considers a reauthorization of the surveillance act. later on c-span3, foreign ambassadors discussed the form perception of the u.s. >> coming up in an hour, the week ahead in washington including the upcoming government funding deadline will be discussed i roll call white house correspondent john bennett and bloomberg congressional reporter. -- alphonso aguilar talks about immigration policies and the latest push for puerto rican statehood. ♪ closedn capitol hill, a door house until this meeting .eaturing steve bannon testimony is part of the panels look into it russia's activity in the 2016 election. all of this goes along as a three-day test as it is three days until a government shutdown . it is generally 16th and this is the "washington journal." the trump administration will allow states to impose -- supporters back to